The mdr1b gene is thought to be a``stress-responsive'' gene, however it is unknown if this gene is regulated by p53 in the whole animal. Moreover, it is unknown if overexpression of mdr1b aects cell survival. The dependence of mdr1b upon p53 for upregulation was evaluated in p53 knockout mice. Wild-type (wt) or p537/7 mice were treated singly or in combination with gamma irradiation (IR) and/or the potent DNA damaging agent, diethylnitrosoamine (DEN). Both IR and DEN induced mdr1b in wild-type animals, but not in the p537/7 mice. IR also upregulated endogenous mdr1b in the H35 liver cell line, and the mdr1b promoter was activated by IR and activation correlated with p53 levels; moreover activation required an intact p53 binding site. Colony survival studies revealed that co-transfection of both mdr1b and p53 dramatically reduced colony numbers compared to cells transfected with either p53 or mdr1b alone and cells microinjected with both mdr1b and p53 had a more dramatic loss in viability compared to cells injected with either expression vector alone. Further studies using acridine orange and ethidium bromide to measure apoptosis revealed that mdr1b caused apoptosis and this was enhanced by p53, however the increased apoptosis required a functional p53 transactivation domain. These studies indicate that mdr1b is a downstream target of p53 in the whole animal and expression of mdr1b facilitates p53-mediated cell death. Oncogene (2001) 20, 303 ± 313.
Introduction
Mammals possess plasma membrane ATP dependent transporters that can confer resistance to structurally diverse amphipathic cytotoxic agents (Gottesman and Pastan, 1993) . While the human MDR1 gene represents the prototype member, genes that are highly related have been cloned from rodents (Gottesman and Pastan, 1993) . The rodent mdr1a and mdr1b genes share greater than 88% identity, are often expressed in the same tissues and can be selectively overproduced during selection for resistance to cytotoxic agents (e.g., taxol, vinblastine, adriamycin (Lothstein et al., 1989) ). Further, selection for drug resistance with ectopically introduced mdr1a or mdr1b expression vectors yields similar drug resistance pro®les for many drugs (Devault and Gros, 1990) . In contrast, the application of cytotoxic drug selective pressure to murine macrophage cells caused a switch in endogenous mdr expression from predominantly mdr1b to mdr1a (Lothstein et al., 1989; Lin et al., 1995) . The basis for the switch is a presumed transcriptional upregulation of mdr1a. Although, the mechanism accounting for this conversion is unknown, it may be hypothesized that high levels of mdr1b are deleterious to cell survival, a concept that is consistent with studies showing that cytotoxic drugs that are not mdr1 substrates as well as oxidative stress induce mdr1b (Ziemann et al., 1999; Thevenod et al., 2000) and that transcriptional upregulation of mdr1b has been correlated with decreased viability (Schrenk et al., 1996) .
Drug sensitivity studies reveal, with respect to drug substrates, almost identical functions between mdr1a and mdr1b (Lothstein et al., 1989) . This redundancy in drug transport seems unnecessary, especially considering that both genes are co-expressed in many tissues, and in some cases at similar levels (e.g., liver, adrenal, colon and lung) (Schinkel et al., 1995) . These ®ndings suggest that mdr1a and mdr1b have additional biological functions independent of drug transport. Indeed, recent studies revealed functional dierences between mdr1a and mdr1b (Valverde et al., 1996) . In particular, mdr1a increases the rate of activation of swelling-activated chloride channels in response to hypo-osmotic conditions, thereby facilitating restoration of cell volume after exposure to hypo-osmotic stress (Valverde et al., 1996) (human MDR1 is mdr1a's functional orthologue in this respect). In contrast, it has been reported that cells overexpressing mdr1b have an impaired ability to activate chloride channels in response to hypo-osmotic conditions (Bond et al., 1998) . Further studies by several groups have suggested that MDR1 plays a role in apoptosis. For example, ectopic overexpression of MDR1 diminishes the apoptotic response induced by growth factor withdrawal (Robinson et al., 1997) decreases complement mediated cytotoxicity (Weisburg et al., 1999) and impairs the activation of caspase-dependent cell death pathways (Kojima et al., 1998; Smyth et al., 1998) . In contrast, it is unknown if mdr1b overexpression aects cell viability.
Wildtype p53 is a transcription factor that plays a critical role as a transducer of cellular stresses in response to environmental cues (Levine, 1997) . Many transcriptional targets of p53 have biological roles in either cell cycle arrest (e.g., p21 or gadd45 (Levine, 1997) ), regulating p53 (e.g., mdm2) (Momand et al., 1992) or modulating apoptosis (e.g., BAX, PIG3). Transcriptional activation by p53 requires at least two copies of the speci®c DNA binding consensus site (rrrCwwGyyy (Zambetti and Levine, 1993 )) located either upstream or downstream of transcriptional initiation (e.g., p21, BAX, mdm2 (Zambetti and Levine, 1993) ). The cellular response to elevated p53 levels as either G1 arrest or apoptosis is cell-type dependent (Levine, 1997) . P53 also suppresses gene transcription (Zambetti and Levine, 1993) and this requires interactions with TAFs and co-repressors (Murphy et al., 1999) . One endogenous target of p53 mediated repression, con®rmed by both transient transfection assays and inactivation of endogenous p53 is the human MDR1 and rat mdr1a (Thottassery et al., 1997) .
Although a previous study suggested in cell culture that the rat mdr1b gene contained a p53 site it was unclear if this p53 site was relevant to the whole animal from these cell culture studies because: (i) the apparent p53 eects were modest (Zhou and Kuo, 1998) , (ii) Figure 1 The rodent mdr1b genes contain a functional conserved p53 DNA binding site. (a) Sequence alignment between mouse and rat mdr1b; (b) Rat and mouse mdr1b bind recombinant p53 in the presence of Ab421 with binding abrogated by speci®c mutations and competitors. (c) Activation of the rat and mouse mdr1b promoters requires wildtype p53 s. The bars represent the average value plus one standard deviation (n=3 ± 4 separate experiments with duplicate determinations) mdr1b enhances p53-dependent cell death V Lecureur et al authentic p53 had not been demonstrated to bind the p53 site and (iii) the p53 site functionally overlapped with a NF-kb site that also positively regulated mdr1b (Zhou and Kuo, 1997) . To approach these issues we used a mouse model to determine if the mdr1b gene was regulated by p53 in the whole animal. The p53 nullizygous animals provided an ideal opportunity to determine if mdr1b was regulated by DNA damage. We found that p53 is required for upregulation of mdr1b in the whole animal because the potent DNA damaging agent, diethylnitrosamine (DEN) only upregulated mdr1b in p53+/+ mice and not in p537/7 mice. Furthermore, because mdr1b is a downstream target of p53 we further determined that mdr1b expression in p53-null cells caused decreased cell survival and co-expression of mdr1b and wt p53 indicated p53 cooperated with mdr1b in decreasing cell survival. These studies are the ®rst to demonstrate that p53 plays an essential role in regulating mdr1b in the whole animal and that mdr1b enhances p53's ability to decrease cell survival.
Results
Rodent mdr1b genes contains a conserved, functional p53 site required for optimal basal activity DNA sequence analysis of the mouse and rat mdr1b genes revealed remarkable similarity between the two genes (92%) and their regulatory sequences (e.g., Ybox, Sp1/Egr-1 (Thottassery et al., 1999) ). Further analysis revealed both genes contained, in almost identical position, two adjacent p53 sites (rrrCwwGyyy) (Figure 1a) . In contrast, the mouse mdr1a, rat mdr1a genes and human MDR1 do not have p53 binding sites (unpublished). To determine if the positionally conserved p53 site in the mdr1b promoters bound authentic p53, gel shift analysis was performed using oligonucleotides to either a p53 consensus site (Nagaich et al., 1997a) , the mouse mdr1b p53 site, rat mdr1b p53 site, or a mutant rat mdr1b with nucleotide substitutions at positions 4 and 7 that eliminate p53 DNA binding (the`C' and`G' at Figure 2 Activation of the rodent mdr1b promoters by p53 requires a p53 binding site. (a) The mdr1b promoter (7250 to +150) was systematically deleted by either PCR or convenient restriction sites. The reporter, p50-2, that contains two consensus p53 binding sites fused to a TATA-inr was used as a positive control for p53 activation. (b) The p53 site in the rat mdr1b promoter was mutated (see Materials and methods) and the reporters containing either the wild-type mdr1b promoter or the promoter with the mutated mdr1b p53 site were transfected into Saos-2 cells in either the presence or absence of p53. (c) The murine mdr1b promoter was either intact or the p53 site deleted followed by transfection as described above Oncogene mdr1b enhances p53-dependent cell death V Lecureur et al positions 4 and 7) (Nagaich et al., 1997b) . Because recombinant p53 proteins do not bind p53 sites, due to conformational restraints (Levine, 1997) , we used an antibody to the C-terminus of p53 that`opens up' p53 into a form competent for sequence speci®c DNA binding (Hupp et al., 1995) . Both the mouse and rat mdr1b genes readily bound authentic p53, and binding was speci®c because it was abrogated by including a speci®c competitor oligonucleotide containing a consensus p53 site. In contrast, the rat mdr1b probe with speci®c p53 mutations did not bind p53 under any circumstances (Figure 1b) .
The functional signi®cance of the rodent mdr1b p53-binding sites was determined by assessing whether wildtype or p53 (Figure 1c ) activated these promoters in Saos-2 cells that lack endogenous p53. Wild-type p53 activated both rodent promoters and induction was speci®c as none of the p53 mutants (V143A, R175H, F241S, R273H or D281G) activated transcription.
To test the role of the p53 site in activation of the mdr1b promoter, we performed either deletion analysis or the mdr1b p53 site was speci®cally mutated at the positions abrogating binding to puri®ed p53 ( Figure  1b) . The rat mdr1b promoter with an intact p53 site was activated over 15-fold by wt p53 (Figure 2a ). As expected, the positive control reporter plasmid (50-2) containing two copies of the muscle-creatine kinase p53 binding site was eciently activated by co-transfecting the same amount of p53 expression plasmid. Notably, either internal deletion (Eco/Nde) or 5' to 3' deletion (7162) of the p53 site caused p53-dependent repression of the resulting promoter. Similarly, mutation of the mdr1b p53 site caused, not unexpectedly, repression by p53 (Figure 2b ). The intact mouse mdr1b promoter was readily activated by p53 and its removal, not unexpectedly, caused p53-mediated repression of the promoter (Figure 2c ). In summary, the rodent mdr1b promoters contain conserved p53 consensus binding sites, bind puri®ed p53 protein in vitro, and are transcriptionally upregulated by wt p53 in transient transfection assays in vivo.
Hepatic DNA damage induces mdr1b gene expression and requires p53 in vivo
We determined if regulation of the mdr1b promoter by p53 was relevant to regulation of the endogenous mdr1b gene in the animal. Acute hepatic exposure to Figure 3 The hepatotoxin diethylnitrosamine (DEN) and ionizing radiation (IR) require p53 to upregulate mdr1b. (a) Mice were treated with a single dose of the indicated concentrations of diethylnitrosamine (DEN) (25, 100 or 150 mg/kg) and 24 h later were sacri®ced, liver samples isolated and prepared for immunoblot analysis of p53 and p21. (b) Northern blot analysis was performed on liver RNA (20 mg) isolated from p53+/+ or p537/7 mice treated with either 150 mg/kg DEN, 10 gray ionizing radiation or a combination of both. The blot was probed, stripped and re-probed successively with cDNAs for p21, E124 and actin. The ethidium bromide stain is shown to indicate the integrity of the RNA. (c) RNAse protection analysis was performed concurrently for mdr1b and actin on the same RNA samples (15 mg) as described in the Materials and methods mdr1b enhances p53-dependent cell death V Lecureur et al diethylnitrosamine (DEN) ethylates DNA at guanine residues after hepatic P450 metabolism and causes subsequent single-strand breaks (Singh and Roscher, 1991) . This form of stress (Levine, 1997) activates p53, a sensor of DNA damage. To determine if DEN induced DNA damage activated p53 in vivo, mice were acutely treated with varying doses of DEN, followed by an analysis of hepatic p21 and p53 levels. These studies revealed that hepatic p21 and p53 were induced in a dose-dependent manner (Figure 3a) , a ®nding consistent with the demonstration that DEN damages DNA. Subsequently, p537/7 and p53+/+ mice were treated with 150 mg/kg DEN and/or 10 Gray ionizing radiation (IR), a form of DNA damage that weakly causes p53 activation in the liver of the intact animal (MacCallum et al., 1996) . Twenty-four hours after treatment livers were harvested and levels of p53 target genes were determined ( Figure 3b ). In untreated p53+/ + animals, p21 was undetectable and gamma irradiation caused a small p21 upregulation. In contrast, DEN alone strongly upregulated p21. DEN-mediated upregulation of p21 required p53 as p21 was not induced by DEN in p537/7 mice. Further studies with EI24, a gene originally isolated by dierential display from cells undergoing etoposide induced apoptosis (Gu et al., 2000) revealed two interesting ®ndings. First, hepatic induction of EI24 by IR required p53 because EI24 was not induced by IR in p537/7 mice. Second, unlike p21, EI24 was induced by DEN treatment in p53-null liver implying that EI24 responded directly to DEN induced damage. The role of p53 in the regulation of hepatic mdr1b was evaluated by an analysis of the RNA from the p53+/+ and p537/7 livers of mice treated with either IR, DEN or IR and DEN (Figure 3c ). After IR, p21 and mdr1b were modestly upregulated in p53+/+ mice (Figure 3b and c). In contrast, DEN strongly increased mdr1b. Interestingly, like p21, mdr1b was not further increased by the combination of DEN and IR. As expected for a gene requiring p53, mdr1b was not induced by DEN or DEN plus IR in p537/7 mice. Thus, p53 is essential for the in vivo upregulation of murine mdr1b.
Gamma irradiation induces mdr1b expression and activates its promoter
Dierent forms of DNA damage cause dierent p53 post-translational modi®cations with varying potential Figure 4 Ionizing radiation induces p53 and activates the mdr1b promoter. (a) H35 cells were irradiated with the indicated doses, 24 h later RNA was isolated, and analysed by northern blot stained with ethidium bromide for 28S RNA or hybridized with an actin cDNA. Mdr1b levels were determined by RNAse protection. (b) Cells were transfected with either rat mdr1b promoter (7250WT) or its p53 mutant (7250MT) reporter. Twenty hours after transfection the cells were irradiated with 10 Gray of g-IR. (c) At the indicated intervals, transfected samples were processed for luciferase activity and p53 expression by immunoblot Figure 5 Mdr1b and p53 cooperatively suppress cell growth in Saos-2 cells. Cells were transfected with either pcDNA3-neo (NEO) pcDNA3-mdr1b, pcDNA3 plus the p53 expression plasmid, SN3 or pcDNA3-mdr1b and SN3. The transfected cells were selected in 1.0 mg/ml G418 for 14 days (a), stained with crystal violet and (b) then enumerated to transactivate p53 targets (Giaccia and Kastan, 1998) . Ionizing radiation (IR), has not been shown to upregulate mdr1b expression nor activate its promoter. To provide a mechanistic basis for our previous observations (Figure 3) , we used the liver cell line, H35 to test this possibility. These cells were irradiated with 5 ± 15 Gray of IR-these doses readily induced p53 and p21 in H35 cells and mdr1b levels were determined (Figure 4) . Expression of mdr1b RNA increased in response to increased IR dose (Figure 4a ). To determine if p53 levels correlated with mdr1b promoter activation we transfected LS180 cells with the mdr1b promoter reporter constructs. After transfection, the cells were irradiated and at intervals simultaneously analysed for both luciferase activity and p53 levels. The transcriptional activity of the mdr1b promoter directly correlated with the p53 level (Figure 4c ) with a 20-fold increase after 24 h (Figure 4b ). In contrast, the mdr1b promoter containing speci®c mutations in the p53 binding site (the same mutations abrogated p53 binding ± see Figure 1b ) was only minimally increased (Figure 4b ) despite the large increase in p53 ( Figure  4c) . Cumulatively, these studies in both cell culture and the whole animal indicate the mdr1b genes contains conserved p53 binding sites that are eciently and readily activated by p53. mdr1b can interact with p53 to decrease cell survival Increased expression of mdr1b has been associated with cytotoxic exposure to the topoisomerase inhibitor, mitoxantrone and a non-mdr1 substrate, methylmethane sulfonate, which causes DNA damage after DNA alkylation (Fardel et al., 1998) . We therefore reasoned that mdr1b might participate in the cytotoxic response after DNA damage. To assess this possibility we evaluated the eect of mdr1b expression on cell viability using colony assays ( Figure 5 ). The p53-null Saos-2 cells were transfected with either pcDNA3, pcDNA3 plus a p53 expression plasmid, SN3 or pcDNA3 containing the mdr1b cDNA (pcDNA3-mdr1b) or pcDNA3-mdr1b plus SN3. The transfectants were selected in 1.0 mg/ml G418 for 14 days and the colonies were visualized with crystal violet and enumerated (Figure 5a ). P53 produced a 46% reduction in the number of colonies and mdr1b also reduced the number of colonies by 30% (Figure 5b ). However, mdr1b and p53 reduced colony numbers by 74% suggesting that they cooperate to inhibit cell growth. In support of this concept, transfection of an mdr1b expression vector (pcDNA3-mdr1b) into p53-null Saos-2 or 10(1) cells readily yielded G418-resistant colonies that stably expressed mdr1b (43 and 18%, respectively); in contrast, transfection of the LS180 cell line (which has wt p53 (Thottassery et al., 1997) ) revealed only neo-resistant clones that failed to express mdr1b after G418 selection (data not shown). Further, the LS180 cells are not generally impaired for expression of exogenous genes because they readily expressed plasmids containing cDNAs for other genes (not shown).
The reduction in colony numbers by mdr1b overexpression could be a consequence of cell death. To directly test the possibility that mdr1b induced apoptosis, we co-microinjected a green¯uorescent protein (GFP) expression plasmid together with either pcDNA3-alone or pcDNA3-mdr1b or the p53 expression plasmid, SN3 alone or SN3 and pcDNA3-mdr1b into the COS-7 cells which are functionally null for p53 (Levine, 1997) (Figure 6 ). The cells co-injected with cDNAs encoding mdr1b and p53 showed dramatic membrane blebbing and nuclear condensation, and detachment from the culture dish, all characteristics of dying/apoptotic cells (Figure 6a ). Besides morphology, we used GFP to quantify the proportion of healthy cells (Figure 6b ). These studies demonstrated that those co-injected with mdr1b and p53 had far fewer healthy GFP cells (8%) compared to either mdr1b (52%) or p53 (26%) alone. Cumulatively, these studies indicate that mdr1b cooperates with p53 to decrease cell viability as measured by: (i) decreased colony survival, (ii) changes in cell morphology characteristic of apoptosis (e.g., membrane blebbing, nuclear condensation, detachment) and (iii) decreased number of viable cells expressing GFP. The colony reduction and microinjection studies demonstrate p53 and mdr1b functionally interact to enhance cell death. To further assess the basis for this interaction we used both acridine orange and ethidium bromide staining of the entire population of cells transfected with various combinations of p53 and/or mdr1b expression vectors (Figure 7a ± c) . Further, we assessed if p53 transactivation function was required (Figure 7c) . Approximately 30 h post-transfection cellular morphology and nuclear condensation were determined (Figure 7a ). Those cells with rounded membranes and bright condensed or fragmented nuclei were enumerated as non-viable (Figure 7b,c) . The topoisomerase poison and cytotoxin, VP-16, was used as a positive control and it profoundly reduced both the number of cells on the plate as well as the viability of the remaining attached cells. Notably, either mdr1b or p53 alone caused over 50% of the attached cells to appear non-viable. However, unlike mdr1b, p53 appeared to have a greater number of cells still attached (Figure 7b ), an outcome that may be attributed to dierent amounts of p53 aecting either cell cycle arrest or apoptosis (Levine, 1997) . When p53 is added to small amounts of mdr1b there is a dramatic enhancement in the loss of attached cells (Figure 7c ) and many of the few that remain are apoptotic. To determine if the p53's enhancement of mdr1b mediated cell death required p53's transcriptional function a p53 with impaired transcriptional activation potential was used ± p53 with mutations in amino acid 22 and 23 (Roemer and Mueller-Lantzsch, 1996) . We found that the apoptosis of mdr1b and 22,23-p53 was not appreciably dierent than 22,23-p53 alone, but much less that of p53 and mdr1b. This ®nding demonstrates that increasing amounts of mdr1b enhance p53 apoptosis and this requires, in part, an intact p53 transcriptional activation domain.
Discussion
Previous studies from our laboratory demonstrated that functional inactivation of wildtype p53 upregulates endogenous MDR1 in human cells and its orthologue, mdr1a, in rodent cells, thus demonstrating that wt p53 represses endogenous mdr1a expression (Thottassery et al., 1997) . These results are consistent with others demonstrating elevated MDR1 expression in breast and colon tumors with deletions or mutations in p53 (Ralhan et al., 1999) . Here we have demonstrated, in both the whole animal and in cells, that mdr1b is a downstream target activated by p53. Moreover, rodent mdr1b promoters have conserved p53 sites that are required for upregulation of mdr1b after DNA damage. Because some downstream targets of p53 play a role in apoptosis (e.g., BAX, EI24 (Gu et al., 2000) ) we also determined if mdr1b overexpression aected cell survival. Mdr1b decreased cell survival alone, but when combined with p53, dramatically increased cell death.
The murine and rat mdr1b promoters are highly similar (Figure 1 ) and this sequence conservation extends to their p53 regulation. First, consensus p53 binding sites are positioned at nearly identical distances upstream from transcriptional initiation and are required for mdr1b promoter activation by p53. Second, functional p53 is required to transcriptionally upregulate mdr1b in vivo and in vitro. As mdr1b is the more primitive of the mdr1 genes (as determined by phylogenetic analysis (Growtree) (Furuya et al., 1997a) ), one interpretation of the current studies is that increased mdr1b decreases cell survival in a p53 and mdr1b dependent fashion. This idea is circumstantially supported by studies showing mdr1b is readily upregulated by cytotoxic agents that are, for the most part, not mdr1 substrates (e.g., 3-methylcholanthracene, a¯atoxinB1, methylmethanesulfonate, mitoxantrone or reactive oxygen (Fardel et al., 1998; Ziemann et al., 1999; Thevenod et al., 2000) ) and mdr1b is transcriptionally upregulated in cells undergoing cell death (Schrenk et al., 1996) . However, given that dierent levels of p53 are linked to dierent cellular outcomes, i.e., low levels of p53 arrest cell growth and high levels induce apoptosis (Levine, 1997 ); mdr1b's role in apoptosis may be dramatically in¯uenced by the cell context. In addition, other signals (e.g., IL-3) regulate mdr1b expression, and may impact how it functionally aects apoptosis. Moreover, mdr1b has a number of phosphorylation sites which like the cystic ®brosis membrane transregulator may regulate function (Naren et al., 1999) . Nonetheless, based upon our ®ndings one would predict that in cells that lack mdr1b, p53-dependent apoptosis would be attenuated. Certainly, future studies can only address this issue when mdr1b 7/7 animals become commercially available.
Our data indicate that, besides being a downstream target of p53, mdr1b interacts with p53 in decreasing cell survival, however at this point we cannot quantitatively distinguish synergistic from additive interaction. Nevertheless, in the presence of p53, our studies reveal that mdr1b potently decreased cell survival as supported by the following: (i) dramatic reduction in colony survival in p53-null Saos-2 cells cotransfected with p53 and mdr1b ( Figure 4) ; (ii) enhanced loss of cell viability after co-microinjection of mdr1b and p53 compared to either expression vector alone ( Figure 5 ) and (iii) only cells with no functional p53 (e.g., Saos-2 and 10(1) cells) stably express mdr1b, whereas cells containing functional wt p53 (e.g., LS180) never express mdr1b stably (not shown) and (iv) mdr1b requires a transcriptionally active p53 to enhance the loss of viable cells from the culture. However, because many genes are upregulated by p53 and some in possibly tissue speci®c patterns, it seems unlikely that upregulation of any one p53 target will be sucient to trigger apoptosis; thus mdr1b may require additional mediators in eecting cell death, and these may be cell context dependent. Moreover, it is possible that factors that alter mdr1b expression may mitigate some of its apoptotic eects. For instance, preliminary studies, suggest that one of the cytokines that mitigates apoptosis, IL-6 (Yonish-Rouach et al., 1991), can Figure 7 Mdr1b increases p53 mediated cell death and requires an intact p53 transactivation domain. Saos-2 cells were transiently transfected with combinations of pcDNA3 (vector=only this plasmid), pcDNA3-mdr1b or the p53 expression plasmids, SN3, or p53 Gln22, Ser23 or treated with VP-16 (epipidophyllotoxin, 100 mM). Thirty hours later, the cells were stained with acridine orange and ethidium bromide and visually inspected (a). The total number of attached cells in a ®eld quanti®ed (white bars) and the cells with both the rounded morphology indicative of apoptosis and green dots characteristic of condensed chromatin and fragmented nuclei (black bars ± b and c). (b) Saos-2 cells were transfected with 10 mg of either pcDNA3-mdr1b and 1 mg CMV-NeoBAM (labeled mdr1b), 1 mg SN3 (p53) and 10 mg pcDNA3 (labeled p53) or 1 mg SN3 and 10 mg pcDNA3-mdr1b (labeled p53+mdr1b).
mdr1b enhances p53-dependent cell death V Lecureur et al decrease mdr1b promoter activation by p53 (unpublished). One obvious issue arising from these studies is how does mdr1b aect p53? Both rodent mdr1b and mdr1a transport drugs, however, chloride channel activation in response to osmotic stress is attributed only to mdr1a, but not mdr1b (Valverde et al., 1996; Bond et al., 1998) . Thus, we speculate that mdr1b overexpression might provoke a physiological change that enhances p53 function although this has not been proven and is the subject of additional studies. Nevertheless this possibility is not unlikely because alterations in intracellular pH aect the level and consequently function of p53 (Thangaraju et al., 1999) . Moreover, a relationship between p53 and ion-channels was demonstrated by recent studies showing potassium channel activation caused apoptosis in a p53-dependent fashion (Chin et al., 1997) and chloride eux may be critical in the apoptotic cascade (Rasola et al., 1999) . Further, a recent study suggests that osmotic alterations enhance p53s function secondary to phosphorylation (Dmitrieva et al., 2000) . Certainly future studies will focus on the possibility that mdr1b sends a signal to aect p53's transactivation function.
Materials and methods

Cells and animals
African Green Monkey COS-7, H35 rat hepatoma, and LS180 colon carcinoma cells (Thottassery et al., 1997) (American Type Culture Collection, Rockville, MD, USA) and Saos-2 cells (Dr Je Sample, St. Jude) were maintained as indicated by ATCC. Irradiation studies were carried out by treating cells and mice with 10 grays of g-irradiation (IR) at 325 rads/min using a 137 Cs source (JL Shepherd, San Fernando, CA, USA). The mice were treated with a single intraperitoneal injection of diethylnitosamine (DEN) at the indicated concentration. P53 male mice (Taconic Farms, Germantown, NY, USA) were housed in the Animal Facilities at St. Jude.
Transient transfections, reporter assays and plasmids
Cells were transfected by calcium phosphate co-precipitation with 10 mg of reporter plasmid and 100 ng of either p53 expression vector or empty vector. Subsequently the cells were washed twice in phosphate buered saline and incubated at least 15 min at room temperature with agitation in 400 mL or Reporter Lysis buer (Promega, Madison, WI, USA) (Thottassery et al., 1999) . Luciferase activity was measured in 20 ± 40 mL samples using a Opticomp Luminometer (MGM Instruments, Hamden, CT, USA) and subsequently normalized to protein content. We were unable to normalize to B-galactosidase, chloramphenicol acetyltransferase or renilla activities as p53 represses the traditional viral promoters that drive expression of these control reporters (Subler et al., 1992) . The following reagents have been previously described: p50-2 , the wt p53 expression plasmid p53 SN3 (Santhanam et al., 1991) , the murine EI24 cDNA (Gu et al., 2000) and p53 Gln 22, Ser23 (Roemer and Mueller-Lantzsch, 1996) . The mdr1b promoter (7250/+150) was ampli®ed by PCR from a mdr1b promoter template (Thottassery et al., 1999) and speci®c mutations were introduced by overlap extension (Thottassery et al., 1999) . The murine mdr1b gene was obtained by PCR ampli®cation using the following primers: upstream: 5'-caa aag cag aag cca gta ttc tgcc-3' and downstream: 5'-gcc aag tgt cca ata cta aaa gtc ccc aac-3'. The murine mdr1b promoter sequence matched the reported sequence (Raymond and and was subcloned into pGL2 basic (Promega, Madison, WI, USA). The rat mdr1b cDNA (kindly provided by Dr Je Silverman, AVMAX, San Francisco, CA, USA) was subcloned into pcDNA3 (Invitrogen, CA, USA).
Western immunoblot analysis
Liver was homogenized as previously described in a glycerolphosphate buer containing an anti-protease cocktail (`complete' Boeheringer-Mannheim; Thottassery et al., 1997) , H35 cells were lysed in RIPA buer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 100 mg/ml PMSF and 1 mg/ml aprotinin). Equal amounts of protein (500 mg) were separated on SDS-polyacrylamide gels, transferred to nitrocellulose membranes, and probed with a polyclonal anti-p53 antibody (Ab-7) (Oncogene Science, Cambridge, MA, USA). Baculovirus expressed human p53 was used as a positive control (Thottassery et al., 1997) . Analysis of p53 in transiently transfected cells was assessed in lysates prepared in 16Reporter lysis buer (Promega, Madison, WI, USA). Analysis of p21 was performed on homogenates of liver with antibody, p21(c-19)-G (Santa Cruz, Santa Cruz, CA, USA).
RNA analysis
Total RNA was isolated from murine liver or H35 cells and analyzed by Northern blot with cDNAs encoding EI24 (Gu et al., 2000) and b-actin. Prehybridization, hybridization with random labeled probes and washing conditions have been previously described (Furuya et al., 1997b) .
Ribonuclease protection assay
Rat mdr1b was analysed in total RNA by RNAse protection assay using the RPA II kit according to the manufacturer's instructions (Ambion, Austin, TX, USA) and using the Ambion rat B-actin antisense probe as a control for RNA integrity. To generate a speci®c rat mdr1b ribonuclease protection probe, the region including codons 643 ± 704 in the rat mdr1b open reading frame was PCR ampli®ed from an authentic rat mdr1b cDNA, cloned into pCRII.1 (Invitrogen, Carlsbad, CA, USA) and sequenced. The insert was subsequently cloned into pGEM7Z(+) (Promega, Madison, WI, USA) and the T7 promoter was used to direct (c) Saos-2 cells were transfected with varying amounts of mdr1b (2.5 or 10 mg pcDNA3-mdr1b) in the absence or presence of 1 mg SN3 (p53). Additional cells were transfected with 1 mg p53 Gln22, Ser23 (22, 23) in the presence or absence of 2.5 mg pcDNA3-mdr1b (labeled 22+23+mdr1b. All DNA was balanced with either pcDNA3 or CMV-NeoBAM. All experiments were repeated three times with each sample run in duplicate per experiment. At least two dierent plasmid preparations were used in these studies synthesis of an antisense mdr1b RNA probe. 32 P-labeled antisense RNA probes were generated by in vitro transcription reactions and antisense RNA hybridized with either 10 or 15 mg of total RNA for 12 ± 16 h. The RNA-RNA hybrids were treated with an RNAse A/T1 mixture, protected fragments separated on a 6% denaturing polyacrylamide gel and visualized by autoradiography. The mouse mdr1b RNAse protection probes were kindly provided by Dr Alfred Schinkel (Netherlands Cancer Institute).
Electromobility shift assay (EMSA)
EMSA assays were performed as described previously (Schuetz et al., 1996) . One strand of oligoncleotide was end-labeled with g-32 P ATP and T4 polynucleotide kinase. The labeled oligonucleotides were puri®ed by Nuctrap (Stratagene, CA, USA). Labeled oligonucleotides were mixed with poly (dI-dC) (1 mg) in a binding buer (Gu et al., 2000) and incubated with recombinant human p53 (100 ng) puri®ed from insect cells (greater than 95% pure and labeled, BV) in either the presence or absence of AB421 (2 mg) and/or a p53 consensus site competitor oligonucleotide at 48C for 30 min. As previously described the monoclonal antibody, pAB421 is required to activate p53 to bind DNA (Hupp et al., 1995) . The samples were electrophoresed on a 5% nondenaturing polyacrylamide gel in 0.256TBE at 48C. The synthetic oligonucleotides used in this study were: a p53 consensus site oligonucleotide, 5'-cta gag c gga cat gcc cgg gca tgt ccg cg-3'. The rat mdr1b p53 site was: 5'-gaa catg tag agacatg tct-3'; For mutant rat mdr1b p53 site the italicized bases are critical for p53 interaction (Zambetti and Levine, 1993) were changed from C to T and G to A. The mouse mdr1b p53 site was the following: 5'-gaa cac gta aag aca agt cta-3'.
Colony assays
The interaction between p53 and mdr1b was functionally assessed in transfection assays. Cells were transfected with either 10 mg of pcDNA3, pcDNA3-mdr1b, or combinations of 1 mg of pSN3 plus 9 mg of pcDNA3 or plus 9 mg pcDNA3-mdr1b. The cells were selected in 1.0 mg/ml G418 for 14 days, stained with crystal violet and quanti®ed for colony formation with an Arktek colony counter (Thottassery et al., 1997) .
Microinjection
Cells were microinjected using a Zeiss inverted microscope with an Eppendorf Transjector (5246) at 40 hPa for 0.4 s and micromanipulator (5171). Cells were plated on glass coverslips 24 h prior to injection in DMEM medium supplemented with 10% FBS. The cells were injected with a green uorescent protein (GFP) expression plasmid (pGreenLantern, Gibco ± BRL) and pcDNA3 (100 ng) or mdr1b-pcDNA3 (100 ng) or a pSN3 (100 ng) expression plasmid, or SN3 and mdr1b (50 ng each), and on average 100 ± 200 cells were injected per sample. Five hours after injection, cells expressing GFP were scored. The number of healthy GFP positive cells were identi®ed by¯uoroescence and enumerated. The GFP positive cells were also monitored for morphological changes, which were documented by photography.
Acridine orange/ethidium bromide apoptosis assay
The interaction between p53 and mdr1b in aecting cell viability was evaluated by ecient transient transfection followed by staining with acridine orange and ethidium bromide (Spector et al., 1998) . Saos-2 cells (2610 5 ) plated on 60 mm dishes were transfected in duplicate with the indicated combination of expression plasmids (mdr1b-pcDNA3 (10.0 or 2.5 mg), and/or SN3 (1.0 mg), and/or p53 Gln22,Ser 23 (1.0 mg)). The total amount of DNA was adjusted to 11 mg of DNA per dish by using either pcDNA3 or CMV-Neo BAM. Approximately 730 h post-transfection the dishes were stained with acridine orange (®nal concentration 4 mg/ml) and ethidium bromide (®nal concentration 4 mg/ml). The cells were then monitored for morphological changes indicative of apoptosis i.e., decreased attachment and rounded membranes. The viable cells appeared uniformly green whereas the early apoptotic cells stain green and have bright green intracellular dots indicative of chromatin condensation and nuclear fragmentation. The proportion of cells having both the morphological appearance of apoptosis and the altered nuclear dye-staining were enumerated.
